This suggests that C18-ceramide may not be the main SL lipid actor for the development of insulin resistance, or possibly that the residual muscle C18-ceramide content (50%) was sufficient to inhibit insulin sensitivity (in opposite to 90% ablation observed in Turpin-Nolan's study). This evidence concerns the gene INS and Insulin resistance.